Why Analysts Say the BioCryst Story Is Changing After Astria Therapeutics Acquisition [Yahoo! Finance]
Astria Therapeutics, Inc. (ATXS)
Company Research
Source: Yahoo! Finance
This modest decrease follows the company's acquisition of Astria Therapeutics and reflects revised expectations for revenue growth and projected synergies. Stay tuned to learn how you can track future developments in BioCryst's evolving market outlook. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value BioCryst Pharmaceuticals. What Wall Street Has Been Saying Recent analyst commentary on BioCryst Pharmaceuticals reflects a dynamic outlook following the company's acquisition of Astria Therapeutics. While most firms remain constructive on the stock, perspectives vary regarding valuation, future growth, and short-term risks. Below is a synthesis of recent viewpoints from leading Wall Street analysts. ?? Bullish Takeaways Cantor Fitzgerald raised its price target on BioCryst to $26 from $24 and maintained an Overweight rating, characterizing the acquisition of Astria Therapeutics as a "terrific" value, even befor
Show less
Read more
Impact Snapshot
Event Time:
ATXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATXS alerts
High impacting Astria Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATXS
News
- Astria Therapeutics (NASDAQ:ATXS) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Astria Stockholders Vote to Approve Acquisition by BioCrystBusiness Wire
- Halper Sadeh LLC Encourages CSGS, JHG, CWAN, ATXS Shareholders to Contact the Firm to Discuss Their RightsPR Newswire
- Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXSPR Newswire
- Halper Sadeh LLC Encourages ATXS, GDOT, UBFO Shareholders to Contact the Firm to Discuss Their RightsGlobeNewswire
ATXS
Earnings
- 11/12/25 - Miss
ATXS
Sec Filings
- 1/26/26 - Form 25-NSE/A
- 1/23/26 - Form S-8
- 1/23/26 - Form S-8
- ATXS's page on the SEC website